2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Biological Processes, Pathogenesis, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Pediatric, Neonatal
PAPER

3327 Single-cell multiomics reveals the convergence of B-lineage identity erosion, quiescence, and adenosine-mediated immune evasion in early measurable residual disease

Qianyun Luo, BS, Enoc Granados Granados Centeno, BSc2, Jacob Peterson3, Rebecca Larue, MS4, Lynn M Heltemes Harris, PhD5, Elisabet Ampudia-Mesias, PhD6, Veronika Bachanova, MD, PhD7, Craig Byersdorfer, MD, PhD8, Michael Farrar, PhD9, Sean I. Tracy, MD, PhD10
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 University of Minnesota, Minneapolis, Minnesota, United States
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Minnesota, Minneapolis, Minnesota, United States, University of Minnesota, Minneapolis, Minnesota, United States
10 University of Minnesota, Minneapolis, Minnesota, United States

Background

Modern B-ALL treatment employs sequential cytotoxic chemotherapy and CD19-directed immunotherapies, yet the biology enabling measurable residual disease to escape both modalities remains poorly understood. Identifying the transcriptional programs and microenvironmental features of persisting blasts is critical for overcoming treatment resistance.

Methods

We performed 10x Flex scRNA-seq with CITE-seq (138-marker panel) on >200,000 cells from bone marrow aspirates of 12 B-ALL patients at early treatment timepoints, 1 paired diagnostic sample, and 2 healthy controls. A three-modality malignancy classifier (BoneMarrowMap atlas mapping error, KNN trajectory distance, and gene-level expression residuals) identified 2,289 high-confidence blasts, stratified by cell cycle state (Tricycle). SCENIC was applied in a 2 x 2 factorial design (quiescent/cycling x blast/healthy progenitor) to identify blast-specific regulons. Adenosine pathway expression was evaluated in blasts and immune cells at both RNA and protein levels. Murine CD19-CAR-T cells (1D328Z) were tested for adenosine sensitivity, and in vivo experiments evaluated pretreatment of CD19-CAR-T cells with a direct AMPK agonist (compound 991).

Results

SCENIC analysis revealed coordinated B-lineage identity erosion in quiescent blasts: PAX5, BACH2, and SPIB regulon activities were uniformly suppressed relative to matched healthy progenitors, with PAX5 targets CD79B and SPIB most severely lost. Quiescent blasts gained TCF7/LEF1 and E2F7/E2F8 regulon activity relative to quiescent healthy progenitors, indicating a malignancy-specific quiescence program. In the single included paired diagnostic-treatment case, Quiescence, Autophagy, TGF- β/diapause, Survival, and Epigenetic drug tolerant persister (DTP) modules were enriched at the treatment timepoint even after controlling for cycling status (all p<10-9, Wilcoxon rank-sum test). GSEA revealed that the Hallmark HYPOXIA module was enriched across all blast-vs-healthy contrasts, regardless of cell cycling status (NES=1.61, FDR<0.03). The hypoxia gene HIF-2a correlated with NT5E/CD73 mRNA across patients (ρ=0.723, p=0.003), suggesting HIF-2a may drive transcription of CD73. As paracrine co-expression of the ectoenzymes CD73 and CD39 is known to support adenosine generation, we further explored the expression of these markers across multiple cell types. CD73 surface protein was expressed on blasts from all patient samples. Macrophages and CD16+ nonclassical monocytes expressed CD39 protein constitutively, while a subset of CD8+ effector T-cells also expressed CD39 as well as the inhibitory adenosine receptor ADORA2A. CD39 was also expressed in 69% of Tregs.

Because our initial findings suggested that both hypoxia and adenosine signaling may limit T-cell attack towards residual blasts, we explored their significance in a syngeneic immunocompetent mouse model of B-ALL. BCR-ABL+ LM138 leukemia cells were injected intravenously into C57BL/6 mice on day 0. Mice received cyclophosphamide conditioning on day 12. By day 14, leukemia was well established (30-50% bone marrow involvement). To overcome hypoxia-driven metabolic dysfunction, CD19-CAR-T cells were preconditioned ex vivo with the direct AMPK agonist compound 991 before infusion. In two small pilot experiments, mice receiving 991-preconditioned CD19-CAR-T cells consistently demonstrated a trend toward prolonged 60-day survival compared with mice receiving standard CD19-CAR-T cells (Odds Ratio = 3.7), with larger validation underway. Activated CD19-CART cells also experienced lower viability after exposure to adenosine (1 mM, 24h) in vitro as compared to untreated CD19-CART cells (p <0.01).

Conclusions

Early MRD in B-ALL is defined by coordinated transcriptional alterations resulting in quiescence, B-lineage transcriptional erosion, metabolic dysfunction and DTP programs that may underlie resistance to both cytotoxic chemotherapy and CD19-CART cells. The broad expression of hypoxia response genes, CD73 on blasts and CD39 on responding immune cells, implies the activity of a trans-cellular adenosine-generating axis, converging on ADORA2A+ T cells, and analogous to inhibitory mechanisms described in solid tumors. Combinatorial strategies targeting hypoxia-induced metabolic dysfunction and the adenosine axis may improve outcomes after CD19-CAR-T therapy administered to patients with MRD.

Sean I. Tracy, MD, PhD: No relevant conflicts of interest to declare.